Video
Why Treatment Fails: Interferons, Immune Rewiring, and Biological Escape Mechanisms.
Professor Curdin Conrad discusses why psoriasis treatments may fail, drawing on immunological mechanisms and relevant…
Professor Curdin Conrad discusses why psoriasis treatments may fail, drawing on immunological mechanisms and relevant…
Watch VideoIPC summarizes presentations from its symposium at the 2026 SID Annual Meeting, including disease interception,…
View ReportIPC Councilor Curdin Conrad reviews conventional oral systemic therapies, including their proper use and recent…
Watch VideoThe 2025 ESDR Congress in Antwerp brought together over 1,000 dermatology researchers. This report summarizes the…
View ReportProfessor Curdin Conrad discusses trained immunity and epigenetic memory in inflammatory diseases, highlighting…
Watch VideoThe 2024 IPC Think Tank Congress Report provides a comprehensive summary of key topics, including the epidemiology of…
Read MoreThe program chair and faculty address questions from IPC Global Webinar 3: "The Full Cycle of Psoriasis Care in 2024:…
Watch VideoDr. Curdin Conrad explores guttate psoriasis and discusses various treatment options and therapies designed to target…
Watch VideoIPC GLOBAL WEBINAR SERIES Program chairs: Curdin Conrad, Switzerland Program faculty: Cristina Echeverría, Argentina…
The 2024 Society for Investigative Dermatology (SID) Annual Meeting was held from May 14 to 18, 2024, in Dallas, Texas,…
Read MoreDr. Curdin Conrad offers insights into the latest advances in psoriasis treatment, highlighting the factors that…
Watch VideoSOCIETY FOR INVESTIGATIVE DERMATOLOGY (SID) | DALLAS, TEXAS Wednesday, May 15 9:00 - 12:00 CDT Program chairs:…
Access the latest insights from the 32nd European Academy of Dermatology and Venereology 2023 Congress (EADV) in…
Read MoreDr. Conrad discusses whether we can now modify the course of the disease or at least prevent the need for ongoing…
Watch VideoThe International Society of Investigative Dermatology (ISID) held its inaugural meeting in Tokyo, Japan, from May 10…
Read MoreThe European Academy of Dermatology and Venereology (EADV) organized its 31st congress in Milano, Italy, under the…
Read MoreINTERNATIONAL SOCIETIES FOR INVESTIGATIVE DERMATOLOGY MEETING (ISID) | TOKYO, JAPAN Wednesday, May 10 11:30 - 15:00…
The Psoriasis: from Gene to Clinic International Congress provides a forum for psoriasis experts from around the world…
Read More| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
A patient doing well on an IL-17 inhibitor is diagnosed with cancer, and the oncologist wants the biologic stopped. It is a call most dermatologists have made without much to stand on: patients with cancer are excluded from psoriasis trials, so the entire evidence base is observational. A new IPC paper in JAAD Reviews takes a position anyway. Per the summary of product characteristics, active malignancy is not a contraindication to any biologic. IL-17 and IL-23p19 inhibitors are first-line, TNF inhibitors and deucravacitinib warrant caution, and cyclosporine is the one to avoid outright. The authors also warn that psoriasis severity is routinely underestimated once a patient is in oncology care: if they meet IPC’s criteria, they are a candidate for systemic therapy regardless of what else is on their problem list. “Too often, systemic psoriasis therapy is discontinued or never initiated in patients with cancer, even when the evidence supports safe and effective options,” says Paolo Gisondi, MD, IPC Councilor and lead author. The post includes the therapeutic options figure, designed as a reference for both specialties to work from, and a slide set for teaching and presentations.
In this article, IPC Board Member Lluís Puig, MD, PhD, gives his expert commentary on two randomized trials showing that ixekizumab plus tirzepatide outperforms ixekizumab alone for skin clearance, joint control, and weight loss in psoriasis and PsA.
IPC is accepting applications for the 2027 International Fellowship Program, a 12-month opportunity for early-career dermatologists and researchers focused on psoriasis. Fellows are matched with IPC Board Members or Councilors for hands-on clinical or research experience, along with virtual mentoring, skills-development classes, and ongoing connections to IPC’s global network throughout the fellowship year. Applications are open until September 30, 2026.
Recognizing GPP in clinical practice can be a challenge, even for experienced dermatologists. IPC’s new five-part training series walks clinicians through the practical skills needed to diagnose and assess GPP with confidence: distinguishing it from plaque psoriasis and other mimicking conditions, and scoring its severity using tools such as the GPPGA and GPPASI. Each module pairs an expert-led video with a case-based exercise, and the series is built to be completed in sequence at your own pace. All five modules are free and open to everyone; watch the videos on your own or work through the assessments as you go. Score 80% or higher on each of the five assessments to earn a Certificate of Completion.
IPC has released a set of summary slides distilling the key findings from its recent publication on psoriasis and metabolic health, published in the Journal of the American Academy of Dermatology (JAAD). The paper outlines five priorities for improving cardiometabolic risk screening and care in patients with psoriasis. Designed for sharing, the slides give clinicians and colleagues an easy way to disseminate the findings.
In this Take Ten with IPC video, IPC Junior Councilor Dr. María Julia Cura discusses paradoxical psoriasis, including its definition and pathogenesis, and reviews clinical case examples, key clinical features, histopathology, predictors of disease severity, and potential treatment options.